The new consortium is aiming to make comprehensive genomic profiling accessible to advanced cancer patients in the US, to help inform their treatment decisions.
The B44 supertype is associated with improved survival in melanoma patients treated with immunotherapy, but less so in NSCLC patients, due to mutational differences.
The company has used its semi-closed electroporation system to manufacture autologous CAR T cells to treat ovarian cancer and leukemia patients in two trials.
A deal with Burning Rock will allow the test to be used in trials and clinics in China, and Myriad will license its technology to French and German pathology labs.
The Phase I trial will assess BBP-398's safety and anti-tumor activity in cancers with MAPK signaling pathway genetic mutations, including mutations in RAS genes.
Using OneThree's AI platform, Jubilant has identified biomarker-defined cancer indications that it hopes to pursue for JBI-802 in human trials next year.
The company fully enrolled a Phase III trial in which patients with DGM1-positive, diffuse large B-cell lymphoma received enzastaurin plus chemo or chemo alone.
In the Phase II trial, FGFR2b-positive gastric cancer patients on bemarituzumab and chemo had better response rates and survival than those just on chemo.
The agency recommended the combination for previously untreated CLL patients with certain genetic mutations, including those with a 17p deletion or TP53 mutation.
Baiyunshan will assume responsibility for developing and commercializing HG030 in mainland China, while HitGen will retain rights in all other territories.
The company decided this after the Keytruda-Yervoy combination did not improve overall survival or progression-free survival compared to Keytruda monotherapy.
The company's T-cell product, PRIME IL-15, which is loaded with an IL-15fc nanogel, led 10 out of 17 advanced solid tumor patients to have stable disease.
The test will use a blood-based biopsy to detect patients with BRCA1, BRCA2, and/or ATM alterations in metastatic castration-resistant prostate cancer.
The company will continue to evaluate several agents, including its c-MET inhibitor APL-101 for patients with a variety of MET dysregulated solid cancers.
The researchers said their findings could explain improved outcomes of sarcomatoid tumors to checkpoint blockade versus antiangiogenic therapies alone.
